Gapping down
In reaction to strong earnings/guidance: MW -38.3%, TNGO -20.2%, GLUU -19.9%, SWIR -18.9%, CMLS -18.6%, CPST -16.3%, PXLW -14%, SKUL -13.4%, GDOT -11.3%, AAOI -9.8%, TRIP -9.6%, ALDR -7.6%, MFLX -7.4%, MMI -7.1%, NEWR -5.6%, CLVS -4.9%, SNTA -4.4%, FICO -4%, GEVO -3.6%, PRAA -3.5%, ACET -3.5%, AMTG -3.4%, MHK -3.3%, TCPI -3.2%, DIOD -3.1%, CLDX -3%, GST -2.4%,SYN -2.1%, BIOC -2.1%, VIP -2%, HAIN -1.9%, KHC -1.9%, INSM -1.8%, HNSN -1.6%, EFC -1.4%, AKAO -1.3%, BBG -1.1%, EOG -1.1%, ABUS -1%
M&A news: NSR -2.3% (agrees to acquire MarketShare Partners for $450 mln ), AZN -1% (acquired ZSPH of ~2.7 bln)
Other news: KBIO -51.8% ( to reduce workforce by ~61%, will explore strategic alternative), CGIX -17.6% (prices 3 mln shares of its common stock at $4.00/share; gross proceeds expected to be $12.0 mln), MRNS -15.9% (to offer and sell shares of its common stock in an underwritten public offering), MCZ -13.6% (entered into $25 mln ATM common stock offering agreement with Ascendiant Capital, reported Q3 results), XOMA-12.6% (Agenus enters into three transactions, including agreement to acquire XOMA's (XOMA) antibody pilot plant manufacturing facility and capabilities ), RDY -12.4% (receipt of a warning letter from the FDA), SNY -6.2% (sets long-term growth objectives at IR seminar; targets sales CAGR between +3-4% 2015-2020), BSTC -5.8% (BioSpecifics Tech reports that Endo International (ENDP) has exercised its early opt-in for CCH to include two new potential indications; lateral thigh fat and plantar fibromatosis), BHP -5.1% (following Samarco incident), EYES -3.7% (disclosed that Medicare payment rate for the Argus II Retinal Prosthesis System may be cut), TCPI -3.2% (announced delay in reporting third quarter 2015 financial results; due to a pending Audit Committee investigation; offers prelim Q3 results), VALE -3% (BHP Billiton and Vale (VALE) are 50 per cent shareholders in the Brazilian company and joint venture, Samarco), SERV -2.3% (announces the sale of ~28.96 mln shares of its common stock by a selling stockholder associated with Clayton, Dubilier & Rice and StepStone Group)
Analyst comments: CREE -5.6% (downgraded to Sell from Neutral at Goldman), SEAS -2.2% (downgraded to Neutral from Buy at Goldman), CMG -1.6% (downgraded to Neutral at Robert W. Baird
)
In reaction to strong earnings/guidance: MW -38.3%, TNGO -20.2%, GLUU -19.9%, SWIR -18.9%, CMLS -18.6%, CPST -16.3%, PXLW -14%, SKUL -13.4%, GDOT -11.3%, AAOI -9.8%, TRIP -9.6%, ALDR -7.6%, MFLX -7.4%, MMI -7.1%, NEWR -5.6%, CLVS -4.9%, SNTA -4.4%, FICO -4%, GEVO -3.6%, PRAA -3.5%, ACET -3.5%, AMTG -3.4%, MHK -3.3%, TCPI -3.2%, DIOD -3.1%, CLDX -3%, GST -2.4%,SYN -2.1%, BIOC -2.1%, VIP -2%, HAIN -1.9%, KHC -1.9%, INSM -1.8%, HNSN -1.6%, EFC -1.4%, AKAO -1.3%, BBG -1.1%, EOG -1.1%, ABUS -1%
M&A news: NSR -2.3% (agrees to acquire MarketShare Partners for $450 mln ), AZN -1% (acquired ZSPH of ~2.7 bln)
Other news: KBIO -51.8% ( to reduce workforce by ~61%, will explore strategic alternative), CGIX -17.6% (prices 3 mln shares of its common stock at $4.00/share; gross proceeds expected to be $12.0 mln), MRNS -15.9% (to offer and sell shares of its common stock in an underwritten public offering), MCZ -13.6% (entered into $25 mln ATM common stock offering agreement with Ascendiant Capital, reported Q3 results), XOMA-12.6% (Agenus enters into three transactions, including agreement to acquire XOMA's (XOMA) antibody pilot plant manufacturing facility and capabilities ), RDY -12.4% (receipt of a warning letter from the FDA), SNY -6.2% (sets long-term growth objectives at IR seminar; targets sales CAGR between +3-4% 2015-2020), BSTC -5.8% (BioSpecifics Tech reports that Endo International (ENDP) has exercised its early opt-in for CCH to include two new potential indications; lateral thigh fat and plantar fibromatosis), BHP -5.1% (following Samarco incident), EYES -3.7% (disclosed that Medicare payment rate for the Argus II Retinal Prosthesis System may be cut), TCPI -3.2% (announced delay in reporting third quarter 2015 financial results; due to a pending Audit Committee investigation; offers prelim Q3 results), VALE -3% (BHP Billiton and Vale (VALE) are 50 per cent shareholders in the Brazilian company and joint venture, Samarco), SERV -2.3% (announces the sale of ~28.96 mln shares of its common stock by a selling stockholder associated with Clayton, Dubilier & Rice and StepStone Group)
Analyst comments: CREE -5.6% (downgraded to Sell from Neutral at Goldman), SEAS -2.2% (downgraded to Neutral from Buy at Goldman), CMG -1.6% (downgraded to Neutral at Robert W. Baird
)